vs
Amphastar Pharmaceuticals, Inc.（AMPH）与CARRIAGE SERVICES INC（CSV）财务数据对比。点击上方公司名可切换其他公司
Amphastar Pharmaceuticals, Inc.的季度营收约是CARRIAGE SERVICES INC的1.7倍（$183.1M vs $105.5M），Amphastar Pharmaceuticals, Inc.净利率更高（13.3% vs 11.6%，领先1.7%），CARRIAGE SERVICES INC同比增速更快（8.0% vs -1.8%），Amphastar Pharmaceuticals, Inc.自由现金流更多（$24.6M vs $6.2M），过去两年Amphastar Pharmaceuticals, Inc.的营收复合增速更高（3.2% vs 1.0%）
安福斯制药是一家上市的美国特种制药企业，公司成立于2004年5月，核心业务为吸入制剂及鼻腔给药产品的研发、生产与销售，聚焦特色医药领域深耕发展。
怡和Cycle & Carriage有限公司是怡和集团在东南亚的投资控股公司，目前该集团持有其75%的股份，是怡和集团在东南亚区域开展资本布局与投资业务的核心平台。
AMPH vs CSV — 直观对比
营收规模更大
AMPH
是对方的1.7倍
$105.5M
营收增速更快
CSV
高出9.8%
-1.8%
净利率更高
AMPH
高出1.7%
11.6%
自由现金流更多
AMPH
多$18.4M
$6.2M
两年增速更快
AMPH
近两年复合增速
1.0%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $183.1M | $105.5M |
| 净利润 | $24.4M | $12.3M |
| 毛利率 | 46.8% | 34.8% |
| 营业利润率 | 19.4% | 23.3% |
| 净利率 | 13.3% | 11.6% |
| 营收同比 | -1.8% | 8.0% |
| 净利润同比 | -35.7% | 24.5% |
| 每股收益（稀释后） | $0.51 | $0.76 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收AMPHCSV
| Q4 25 | $183.1M | $105.5M | ||
| Q3 25 | $191.8M | $102.7M | ||
| Q2 25 | $174.4M | $102.1M | ||
| Q1 25 | $170.5M | $107.1M | ||
| Q4 24 | $186.5M | $97.7M | ||
| Q3 24 | $191.2M | $100.7M | ||
| Q2 24 | $182.4M | $102.3M | ||
| Q1 24 | $171.8M | $103.5M |
净利润AMPHCSV
| Q4 25 | $24.4M | $12.3M | ||
| Q3 25 | $17.4M | $6.6M | ||
| Q2 25 | $31.0M | $11.7M | ||
| Q1 25 | $25.3M | $20.9M | ||
| Q4 24 | $38.0M | $9.9M | ||
| Q3 24 | $40.4M | $9.9M | ||
| Q2 24 | $37.9M | $6.3M | ||
| Q1 24 | $43.2M | $7.0M |
毛利率AMPHCSV
| Q4 25 | 46.8% | 34.8% | ||
| Q3 25 | 51.4% | 35.3% | ||
| Q2 25 | 49.6% | 35.2% | ||
| Q1 25 | 50.0% | 35.3% | ||
| Q4 24 | 46.5% | 34.4% | ||
| Q3 24 | 53.3% | 35.2% | ||
| Q2 24 | 52.2% | 36.2% | ||
| Q1 24 | 52.4% | 36.0% |
营业利润率AMPHCSV
| Q4 25 | 19.4% | 23.3% | ||
| Q3 25 | 13.2% | 17.0% | ||
| Q2 25 | 24.2% | 23.5% | ||
| Q1 25 | 21.9% | 29.5% | ||
| Q4 24 | 24.2% | 21.6% | ||
| Q3 24 | 29.8% | 22.7% | ||
| Q2 24 | 30.3% | 18.0% | ||
| Q1 24 | 27.9% | 18.8% |
净利率AMPHCSV
| Q4 25 | 13.3% | 11.6% | ||
| Q3 25 | 9.0% | 6.4% | ||
| Q2 25 | 17.8% | 11.5% | ||
| Q1 25 | 14.8% | 19.5% | ||
| Q4 24 | 20.4% | 10.1% | ||
| Q3 24 | 21.1% | 9.8% | ||
| Q2 24 | 20.8% | 6.1% | ||
| Q1 24 | 25.1% | 6.7% |
每股收益（稀释后）AMPHCSV
| Q4 25 | $0.51 | $0.76 | ||
| Q3 25 | $0.37 | $0.41 | ||
| Q2 25 | $0.64 | $0.74 | ||
| Q1 25 | $0.51 | $1.34 | ||
| Q4 24 | $0.74 | $0.62 | ||
| Q3 24 | $0.78 | $0.63 | ||
| Q2 24 | $0.73 | $0.40 | ||
| Q1 24 | $0.81 | $0.45 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $282.8M | $1.7M |
| 总债务越低越好 | $608.7M | — |
| 股东权益账面价值 | $788.8M | $254.8M |
| 总资产 | $1.6B | $1.3B |
| 负债/权益比越低杠杆越低 | 0.77× | — |
8季度趋势，按日历期对齐
现金及短期投资AMPHCSV
| Q4 25 | $282.8M | $1.7M | ||
| Q3 25 | $276.2M | $1.2M | ||
| Q2 25 | $231.8M | $1.4M | ||
| Q1 25 | $236.9M | $4.6M | ||
| Q4 24 | $221.6M | $1.2M | ||
| Q3 24 | $250.5M | $1.3M | ||
| Q2 24 | $217.8M | $1.5M | ||
| Q1 24 | $289.6M | $1.7M |
总债务AMPHCSV
| Q4 25 | $608.7M | — | ||
| Q3 25 | $608.6M | — | ||
| Q2 25 | $607.7M | — | ||
| Q1 25 | $603.9M | — | ||
| Q4 24 | $601.6M | — | ||
| Q3 24 | $596.4M | — | ||
| Q2 24 | $586.9M | — | ||
| Q1 24 | $594.0M | — |
股东权益AMPHCSV
| Q4 25 | $788.8M | $254.8M | ||
| Q3 25 | $776.7M | $242.1M | ||
| Q2 25 | $757.5M | $235.4M | ||
| Q1 25 | $751.3M | $223.1M | ||
| Q4 24 | $732.3M | $208.6M | ||
| Q3 24 | $727.7M | $198.1M | ||
| Q2 24 | $713.3M | $187.9M | ||
| Q1 24 | $672.4M | $179.6M |
总资产AMPHCSV
| Q4 25 | $1.6B | $1.3B | ||
| Q3 25 | $1.7B | $1.3B | ||
| Q2 25 | $1.6B | $1.3B | ||
| Q1 25 | $1.6B | $1.3B | ||
| Q4 24 | $1.6B | $1.3B | ||
| Q3 24 | $1.5B | $1.3B | ||
| Q2 24 | $1.5B | $1.3B | ||
| Q1 24 | $1.6B | $1.3B |
负债/权益比AMPHCSV
| Q4 25 | 0.77× | — | ||
| Q3 25 | 0.78× | — | ||
| Q2 25 | 0.80× | — | ||
| Q1 25 | 0.80× | — | ||
| Q4 24 | 0.82× | — | ||
| Q3 24 | 0.82× | — | ||
| Q2 24 | 0.82× | — | ||
| Q1 24 | 0.88× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $32.9M | $14.1M |
| 自由现金流经营现金流 - 资本支出 | $24.6M | $6.2M |
| 自由现金流率自由现金流/营收 | 13.4% | 5.9% |
| 资本支出强度资本支出/营收 | 4.5% | 7.5% |
| 现金转化率经营现金流/净利润 | 1.35× | 1.15× |
| 过去12个月自由现金流最近4个季度 | $121.2M | $40.1M |
8季度趋势，按日历期对齐
经营现金流AMPHCSV
| Q4 25 | $32.9M | $14.1M | ||
| Q3 25 | $52.6M | $24.7M | ||
| Q2 25 | $35.6M | $8.1M | ||
| Q1 25 | $35.1M | $13.8M | ||
| Q4 24 | $29.0M | $9.3M | ||
| Q3 24 | $60.0M | $20.9M | ||
| Q2 24 | $69.1M | $2.2M | ||
| Q1 24 | $55.3M | $19.7M |
自由现金流AMPHCSV
| Q4 25 | $24.6M | $6.2M | ||
| Q3 25 | $47.2M | $18.0M | ||
| Q2 25 | $25.0M | $5.2M | ||
| Q1 25 | $24.4M | $10.6M | ||
| Q4 24 | $16.6M | $4.9M | ||
| Q3 24 | $46.2M | $16.2M | ||
| Q2 24 | $63.1M | $-1.4M | ||
| Q1 24 | $46.5M | $16.2M |
自由现金流率AMPHCSV
| Q4 25 | 13.4% | 5.9% | ||
| Q3 25 | 24.6% | 17.5% | ||
| Q2 25 | 14.3% | 5.1% | ||
| Q1 25 | 14.3% | 9.9% | ||
| Q4 24 | 8.9% | 5.0% | ||
| Q3 24 | 24.1% | 16.1% | ||
| Q2 24 | 34.6% | -1.4% | ||
| Q1 24 | 27.1% | 15.6% |
资本支出强度AMPHCSV
| Q4 25 | 4.5% | 7.5% | ||
| Q3 25 | 2.8% | 6.5% | ||
| Q2 25 | 6.1% | 2.8% | ||
| Q1 25 | 6.3% | 3.0% | ||
| Q4 24 | 6.7% | 4.5% | ||
| Q3 24 | 7.2% | 4.6% | ||
| Q2 24 | 3.3% | 3.5% | ||
| Q1 24 | 5.1% | 3.4% |
现金转化率AMPHCSV
| Q4 25 | 1.35× | 1.15× | ||
| Q3 25 | 3.03× | 3.76× | ||
| Q2 25 | 1.15× | 0.69× | ||
| Q1 25 | 1.39× | 0.66× | ||
| Q4 24 | 0.76× | 0.94× | ||
| Q3 24 | 1.48× | 2.11× | ||
| Q2 24 | 1.82× | 0.34× | ||
| Q1 24 | 1.28× | 2.83× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
AMPH
| Other Products | $62.4M | 34% |
| Baqsimi | $46.7M | 26% |
| Primatenemist | $27.9M | 15% |
| Epinephrine | $17.1M | 9% |
| Lidocaine | $14.9M | 8% |
| Glucagon | $14.1M | 8% |
CSV
| Propertyand Merchandise | $47.8M | 45% |
| Cemetery Interment Rights | $24.8M | 23% |
| Merchandise | $18.9M | 18% |
| Other Revenue | $10.2M | 10% |
| Other | $3.9M | 4% |
